{
    "2018-04-25": [
        [
            {
                "time": "2018-04-26",
                "original_text": "Pre-Market Earnings Report for April 26, 2018: ABBV, PEP, MO, UNP, BMY, COP, TWX, UPS, RTN, CME, GM, ITW",
                "features": {
                    "keywords": [
                        "earnings",
                        "pre-market",
                        "ABBV",
                        "BMY"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "consumer goods",
                        "industrials"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX",
                "features": {
                    "keywords": [
                        "Q1 earnings",
                        "drug stock",
                        "ABBV",
                        "BMY"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "What's in the Cards for Inogen (INGN) This Earnings Season?",
                "features": {
                    "keywords": [
                        "earnings season",
                        "Inogen",
                        "INGN"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "Shire willing to back $64 billion Takeda bid, market signals doubts",
                "features": {
                    "keywords": [
                        "Shire",
                        "Takeda",
                        "bid",
                        "market doubts"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "AbbVie Submits Biologics License Application to U.S. FDA for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "FDA",
                        "Risankizumab",
                        "psoriasis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "A Look at Biogen’s Performance in 1Q18",
                "features": {
                    "keywords": [
                        "Biogen",
                        "1Q18",
                        "performance"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study in Japanese Patients",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "rheumatoid arthritis",
                        "efficacy endpoints"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-24",
                "original_text": "Why Incyte Stock Fell ~9% on April 24",
                "features": {
                    "keywords": [
                        "Incyte",
                        "stock fell",
                        "April 24"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "Gilead Sciences’ Inflammation Research Is Seeing Rapid Progress",
                "features": {
                    "keywords": [
                        "Gilead Sciences",
                        "inflammation research",
                        "rapid progress"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-04-26",
                "original_text": "Supreme Court upholds legality of patent review process",
                "features": {
                    "keywords": [
                        "Supreme Court",
                        "patent review",
                        "legality"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "legal",
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}